CinCor Pharma, Inc. (CINC)
Chart Events
Performance Outlook
| Previous Close | 28.90 |
| Open | 28.91 |
| Bid | 28.88 x 800 |
| Ask | 28.90 x 800 |
| Day's Range | 28.84 - 29.06 |
| 52 Week Range | 10.53 - 43.15 |
| Volume | |
| Avg. Volume | 607,026 |
| Market Cap | 1.263B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.40 |
| Earnings Date | Nov 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CINC
Related Research
- CinCor Pharma, Inc.Daily – Vickers Top Buyers & Sellers for 12/27/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
- American City Business Journals
CinCor CEO: acquisition by AstraZeneca was more than a year in the making
Before CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant.
- Motley Fool
Why These Two Biotech Stocks Blasted Higher This Week
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence.
- Zacks
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More
Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.
